DON'T BUY

One of the worst energy names. The CEO and board did one of the word acquisitions in history. When the market wanted natural gas, they added liquids exposure. Are the worst-performing nat gas stock in North America. No upside. An activist has put members on the board.

DON'T BUY

They underperformed a lot last year, but have been righting the ship after disappointing quarters. Has deep value, trading at 4x, a 15% free cash flow yield, though worried about inventory depth in the Permian. He must prefers Canadian oil sand companies (solid balance sheet, long inventories, execution, share buybacks).

COMMENT

Has done a great job of taking market focus off of Base Plant mine depletion down the road. It trades at a slight premium to Cenovus, which SU could buy, but he hopes not.

BUY

Has deep assets, which they won't sell for 9-12 months, as they add others. He can't own every midcap, though this is good.

TOP PICK

One of his largest holdings. It has sold off from tariff worries, just hitting a one-year low. They have 35 years of stay-flat inventory. Over 5 years, will grow production 25% while buying back half their shares as they pay a dividend. At $70, will trade at 4x cash flow and 13% free cash flow yield. At $80, they could buyback 80% of shares over 5 years. Is way oversold. Targets $30 in a year.

(Analysts’ price target is $31.25)
TOP PICK

Buy any dip. They will modestly grow production over 5 years and buy 68% of shares at the current oil price; at $80 they could almost privatize. At $70 oil in 5 years, they will free cash flow at the current share price. Has 50 years of stay-flat inventory. At flat oil, will go from 3.9x cash flow this year, 3.2x in 2026 and 0.3x in 2029.

(Analysts’ price target is $6.42)
TOP PICK

Best way to get Canadian nat gas exposure. They just signed a deal with Exxon, selling 25% of nat gas at international prices. Have deep, deep inventory. Is cheap to US peers. Pays a 3% dividend. He's bullish natural gas given AI and data centres.

(Analysts’ price target is $33.22)
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O’Reilly

We reiterate RPRX as a TOP PICK.  This unique pharma company has investments in 35 jointly developed royalty products, with the largest pharma companies and has several new joint products in development.  It trades at 17x earnings, 2.1x book and supports a 12% ROE.  We recommend trailing up the stop (from $26) to $29, looking to achieve $41 — upside potential of 25%.  Yield 2.6%

(Analysts’ price target is $41.00)
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O’Reilly

We reiterate MCY, a provider of insurance in California as a TOP PICK.  The company recently reported the impact from the LA fires will not be as bad as feared and that liquidity remains strong.  It trades at 9x earnings, 1.6x book and supports a robust 26% ROE.  We recommend trailing up the stop (from $35) to $40, looking to achieve $69 — upside potential over 25%.  Yield 2.3% 

(Analysts’ price target is $80.00)
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O’Reilly

We reiterate SBS, Brazil’s water treatment and sewage management utility as a TOP PICK.  Aside from offering global diversification, it operates in a conservative space.  It trades at 15x earnings, 1.6x book and supports a ROE of 27%.  We continue to recommend a stop at $14, looking to achieve $21 — upside potential over 25%.  Yield 3.1%

(Analysts’ price target is $20.79)
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Feb 13/25, Down 12.3%)Stockchase Research Editor: Michael O’Reilly

Our PAST TOP PICK with ASO has triggered its stop at $47.  To remain disciplined, we recommend covering the position at this time.  When combined with our previous guidance, this will result in a net investment loss of 10%.  

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Oct 03/24, Down 8.9%)Stockchase Research Editor: Michael O’Reilly

Our PAST TOP PICK with CNR has triggered its stop at $141.  To remain disciplined, we recommend covering the position at this time.  

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Mar 04/25, Down 8.8%)Stockchase Research Editor: Michael O’Reilly

Our PAST TOP PICK with VEON has triggered its stop at $40.  To remain disciplined, we recommend covering the position at this time.  When combined with our previous guidance, this will result in a net investment gain of 16%.  

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Mar 04/25, Up 31%)Stockchase Research Editor: Michael O’Reilly

Our PAST TOP PICK with GGAL has triggered its stop at $64.  To remain disciplined, we recommend covering the position at this time.